Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma

Wang, Haohao; Wu, Di; Wang, Pan; Gao, Chunyu; Teng, Hongbo; Liu, Dong; Zhao, Yan; Du, Rui

doi:10.1016/j.biopha.2023.115485

Cited by 2 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GalNAc coupling to asialoglycoprotein, a receptor abundantly expressed on hepatocytes, also emerges as a promising strategy, overcoming hurdles associated with drug resistance and improving the efficiency of liver-specific drug delivery[ 10 , 11 ]. The proliferation of receptors such as transferrin receptor and folic acid receptor that correspond to the tumor’s increased demand of essential nutrients are further targets that show promises for ligand-receptor mediated drug delivery[ 12 , 13 ]. Lastly, strategies to facilitate endosome escape, such as glutathione-responsive environmentally sensitive nanocarriers, are additional focuses in ligand-mediated nanotherapy[ 7 , 14 ].…”

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

“…The tumor microenvironment in hepatocellular carcinoma and over-expressed receptors on tumor cells including anti-glypican-3, asialoglycoprotein, transferrin receptor, folic acid receptor, Axl and integrins. These receptors on tumor cells are prime targets of nanontherapy, such as sorafenib loaded polymer-based nanoparticles[ 8 - 13 , 16 ]. GPC3: Anti-glypican-3; FAR: Folic acid receptor; TfR: Transferrin receptor; ASGPR: Asialoglycoprotein.…”

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

See 1 more Smart Citation

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Lee,

Yuan

2024

World J Hepatol

View full text Add to dashboard Cite

In this editorial we comment on the review by Zhou et al reviewing the landscape of nanomedicine in the treatment of hepatocellular carcinoma (HCC). We focus on the immense potential of nanotechnology, particularly ligand-receptor mediated nanotherapy, in revolutionizing the treatment landscape of HCC. Despite advancements in multidisciplinary treatment, HCC remains a significant global health challenge. Ligand-mediated nanotherapy offers the opportunity for precise drug delivery to tumor sites, targeting specific receptors overexpressed in HCC cells, thereby enhancing efficacy and minimizing side effects. Overcoming drug resistance and aggressive tumor biology is facilitated by nanomedicine, bypassing traditional hurdles encountered in chemotherapy. Examples include targeting glypican-3, asialoglycoprotein, transferrin receptor or folic acid receptors, capitalizing on their over-expression in tumor cells. The ability for multi-receptor targeting through dual-ligand nanoparticle modification holds the prospect of further enhancement in specificity and efficacy of directed therapy. However, challenges including immune responses, reproducibility in nanoparticle synthesis, and production scalability remain. Future directions involve refining targeting strategies, improving drug release mechanisms, and streamlining production processes to enable personalized and multifunctional nanotherapies. Overall, the integration of nanotherapy in HCC treatment holds immense promise, but continued partnership and effort are needed in offering hope for more effective, precise, and accessible clinical care in the management of HCC.

show abstract

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

Section: Application Of Nanotherapy In Hccmentioning

confidence: 99%

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Lee,

Yuan

2024

World J Hepatol

View full text Add to dashboard Cite

show abstract

Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy

Zhou,

Li,

Dang

2024

World J Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a major challenge to global health due to its high morbidity and mortality. Conventional chemotherapy is usually targeted to patients with intermediate to advanced stages, but it is often ineffective and suffers from problems such as multidrug resistance, rapid drug clearance, nonspecific targeting, high side effects, and low drug accumulation in tumor cells. In response to these limitations, recent advances in nanoparticle-mediated targeted drug delivery technologies have emerged as breakthrough approaches for the treatment of HCC. This review focuses on recent advances in nanoparticle-based targeted drug delivery systems, with special attention to various receptors overexpressed on HCC cells. These receptors are key to enhancing the specificity and efficacy of nanoparticle delivery and represent a new paradigm for actively targeting and combating HCC. We comprehensively summarize the current understanding of these receptors, their role in nanoparticle targeting, and the impact of such targeted therapies on HCC. By gaining a deeper understanding of the receptor-mediated mechanisms of these innovative therapies, more effective and precise treatment of HCC can be achieved.

show abstract

Albumin nanoparticles and their folate modified counterparts for delivery of a lupine derivative to hepatocellular carcinoma

Cited by 2 publications

References 53 publications

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?

Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy

Contact Info

Product

Resources

About